Font Size

Understanding Lung Cancer Medications (cont.)

Antimetabolites to Treat Lung Cancer

Gemcitabine (Gemzar) is a newer drug in this class that inhibits DNA production.

  • Who should not use these medications: Persons with allergy to gemcitabine should not take it.
  • Schedule: Gemcitabine is given as an IV injection each week for the first 3 weeks of each 4-week chemotherapy cycle.
  • Drug or food interactions: Gemcitabine may increase the effects of warfarin (Coumadin).
  • Side effects: Gemcitabine may cause a person to bleed or to develop infections more easily. A doctor will check blood and urine for abnormalities that may be caused by these drugs.
    • A doctor should be contacted immediately if any of the following side effects occur:
      • Unexplained fever, chills, or sore throat
      • Severe nausea, vomiting, or diarrhea
      • Unusual bleeding or bruising
      • Small red or purple dots on the skin
      • Yellowing of skin or eyes
      • Wheezing or trouble breathing
      • Severe rash or hives
      • Bloody or cloudy urine
    • Other side effects include the following:
      • Poor appetite
      • Diarrhea or constipation
      • Muscle pain
      • Hair loss
      • Mild rash
      • Numbness, tingling, or mild swelling in the feet and hands
      • Tiredness

Medically Reviewed by a Doctor on 8/3/2016
Medical Author:
Medical Editor:
Medical Editor:
Medical Editor:

Must Read Articles Related to Understanding Lung Cancer Medications

Non-Small-Cell Lung Cancer
Non-Small-Cell Lung Cancer Non-small-cell lung cancer is one of two types of learn more >>
Small-Cell Lung Cancer
Small-Cell Lung Cancer When cells of the lung start growing rapidly in an uncontrolled manner, the condition is called lung cancer. Lung cancer can affect any part of the lung. Small-...learn more >>

Read What Your Physician is Reading on Medscape

Lung Cancer, Oat Cell (Small Cell): Treatment & Medication »

Small cell lung cancer (SCLC) differs from other lung cancer types because of its rapid growth and propensity for early dissemination.

Read More on Medscape Reference »

Medical Dictionary